Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
Nature Medicine 23, 1146 (2017).
doi:10.1038/nm.4396
Authors: Chad E Mire, Robert W Cross, Joan B Geisbert, Viktoriya Borisevich, Krystle N Agans, Daniel J Deer, Megan L Heinrich, Megan M Rowland, Augustine Goba, Mambu Momoh, Mathew L Boisen, Donald S Grant, Mohamed Fullah, Sheik Humarr Khan, Karla A Fenton, James E Robinson, Luis M Branco, Robert F Garry & Thomas W Geisbert
There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.
Source: Nature Medicine - Category: General Medicine Authors: Chad E Mire Robert W Cross Joan B Geisbert Viktoriya Borisevich Krystle N Agans Daniel J Deer Megan L Heinrich Megan M Rowland Augustine Goba Mambu Momoh Mathew L Boisen Donald S Grant Mohamed Fullah Sheik Humarr Khan Karla A Fenton James E Robinson Luis Tags: Brief Communication Source Type: research
More News: African Health | Chad Health | Ebola | Endemics | General Medicine | Grants | Lassa Fever